tbuckley/cabot-search huggingface dataset:
PTH-088 We’re Still not Immune to Immunisations in IBD: Abstract PTH-088 Table 1
Authors: J Heffernan, S Ravindran, J Medcalf, L Macken, A Li
Journal: Gut (2016)

<h3>Introduction</h3> Over the past decade, there has been an increasing uptake of immunomodulator therapy in the treatment of Inflammatory Bowel Disease (IBD). The current British Society of Gastroenterology (BSG) and European Crohn’s and Colitis Organisation (ECCO) guidelines highlight the importance of influenza, pneumococcal, human papilloma virus, varicella and hepatitis B vaccination. Our previous audit in 2014 described 75% uptake of any vaccination in these patients. Here we present the re-audit after an intervention, where a letter was sent to general practitioners (GPs) to promote immunisation awareness. <h3>Methods</h3> 100 consecutive IBD patients attending the general gastroenterology outpatient clinic were asked to complete a questionnaire. All forms of IBD were included. Information regarding medication, infections and immunisation status were recorded. Results were analysed using the statistical package for the social sciences (SPSS). <h3>Results</h3> Of the 100 questionnaires returned, 3 were excluded due to incomplete completion. Median age was 46 (19–84). Of the IBD subtypes, 48 (49%) patients had Crohn’s, 34 (35%) had ulcerative colitis and 15 (16%) had colitis of unknown aetiology (CUTE); male to female ration was 48:52%. 92% of patients with IBD had medication prescribed in the past 6 months. Within this group, 59% had been on mesalazine, 38% on thiopurines, 36% on steroids and 12% on anti tumour necrosis factor (anti-TNF) agents. Overall, 68% of immunosuppressed patients received some form of immunisation in the preceding 6 months and, of these, 28% had some form of infection reported. In total, 44% of patients had immunosuppressant advice given and 29% of patients had vaccination advice. There was no statistical difference in the baseline characteristics of patients and prescribed medication compared to 2014. Despite engagement with primary care, there was no significant difference in the uptake of immunisation in the IBD population. In fact, there were statistically lower rates of Influenza and Pneumovax vaccination in the 2015 cohort (P &lt; 0.05). The only statistical improvement was in HPV vaccination (adjusted) (<i>see table</i>). <h3>Conclusion</h3> Current guidelines state that influenza, pneumococcal and HPV vaccination be considered for all IBD patients. Despite the results of our previous audit there does not appear to be an improvement in vaccination rates. A weakness in the current approach is that information is received by GPs at differing intervals to when a patient is seen. It may be that a targeted, patient-specific letter is sent to GPs with an attached acknowledgement receipt to improve vaccination rates. <h3>Disclosure of Interest</h3> None Declared
Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma
Authors: Taxiarchis Kourelis, Shaji K Kumar, Geetika Srivastava, Morie A Gertz, Martha Q Lacy, Francis K Buadi, Suzanne R Hayman, Steven R Zeldenrust, Nelson Leung, Robert Kyle, Stephen Russell, David Dingli, John A Lust, Yi Lin, Prashant Kapoor, Arleigh McCurdy, Vincent Rajkumar, Angela Dispenzieri
Journal: Blood (2013)
Analysis of the Incidence of Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Registration and Compassionate-Use Trials of Ibritumomab Tiuxetan Radioimmunotherapy (RIT).
Authors: Myron S. Czuczman, Christos Emmanouilides, Mohamed Darif, Thomas E. Witzig, Leo I. Gordon, Steven Revell, Katie Vo, Arturo Molina
Journal: Blood (2006)
Meta Analysis of Grade 3 and/or 4 Toxicities in Follicular (FL) and Mantle Cell (MCL) Non-Hodgkin Lymphoma (NHL) Patients Receiving Maintenance Rituximab (MR): Impact of Schedule, Histology, and Induction Regimen
Authors: Chadi Nabhan, Dana Villines, Brian C-H Chiu, Nicholas J. Ollberding, Tina V. Valdez, Michele Ghielmini, Shu-Fang H. Schmitz, Sonali M. Smith
Journal: Blood (2012)
Over-Expression of the Mas Receptor Decreases Arterial Thrombosis Risk in B2R KO Mice by Elevating NO and Prostacyclin and Reducing GPVI Activation
Authors: Chao Fang, Evi Stavrou, Alec A Schmaier, Gregory N Adams, Marvin T. Nieman, Gretchen LaRusch, Matthew Bilodeau, Fakhri Mahdi, Mark Warnock, Alvin H. Schmaier
Journal: Blood (2011)
Molecular Characterization of Hemoglobinopathies and Red Cell Enzymopathies in the Czech and Slovak Populations: An Update
Authors: Martina Divoka, Renata Mojzikova, Lucie Piterkova, Pavla Pospisilova, Martina Partschova, Monika Horvathova, Dagmar Pospisilova, Zuzana Laluhova Striezencova, Jaroslav Cermak, Karel Indrak, Vladimir Divoky
Journal: Blood (2011)
Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study
Authors: Christopher Flowers, Chadi Nabhan, Neil E. Kay, Anthony Mato, Nicole Lamanna, David L. Grinblatt, Thomas J. Kipps, Mark Kozloff, Kristen Sullivan, E. Dawn Flick, Pavel Kiselev, Shriya Bhushan, Arlene S. Swern, Jeff P. Sharman
Journal: Blood (2015)
PTH-007 Non-Radical, Stepwise Complete Endoscopic Resection of Barrett’s Epithelium in Short Segment Barrett’s Oesophagus is Effective with Low Stricture Rate
Authors: A Koutsoumpas, B Sgromo, R Gillies, LM Wang, AA Bailey, R Marshall, N Maynard, B Braden
Journal: Gut (2016)

<h3>Introduction</h3> Radical endoscopic ablation of Barrett’s epithelium performing 4–6 endoscopic resections during the same endoscopic session has been shown to result in complete Barrett’s ablation but has a high stricture rate (40–80%). Therefore radiofrequency ablation is preferred for the ablation of Barrett’s epithelium after endoscopic mucosal resection (EMR) of visible nodules. We investigated whether non-radical, stepwise endoscopic mucosal resection with maximal 2 endoscopic resections per endoscopic session can result in complete remission of intestinal metaplasia and dysplasia in short segment Barrett’s oesophagus. <h3>Methods</h3> We analysed our database of patients undergoing oesophageal EMR for early neoplasia in Barrett’s oesophagus from 2009 to 2014. Patients showing poorly differentiated cancer or advanced cancer (&gt;T1sm<sub>2</sub>) after staging EMR were excluded. In patients suitable for further endoscopic therapy, EMR was performed using maximal two band ligation mucosectomies per endoscopic session; thereafter followup was 3 monthly and EMR was repeated as required for Barrett’s ablation. If no dysplasia was detected after a year, the follow up interval was increased to 6 months. <h3>Results</h3> 118 patients underwent staging EMR for early Barrett’s neoplasia. Subsequently, 27 patients underwent surgery/chemotherapy due to deep submucosal or more advanced tumour stages or were managed conservatively depending on patient’s fitness, comorbidities and choice. 91 patients with HGD (48), intramucosal (38) or submucosal cancer (5) in the resected nodule underwent further endoscopic therapy with a mean follow-up of 24 months (8–36 months IQR). Remission of dysplasia/neoplasia was achieved in 94.5% after 12 months treatment. Stepwise endoscopic Barrett’s resection resulted in complete Barrett’s ablation in 36 patients (39.6%) in a mean of 4 sessions. 40 patients (43.9%) had a short circumferential Barrett’s segment (C &lt; 3 cm). In this group, repeated EMR achieved complete Barrett’s ablation in 85.0%. One patient developed a stricture (1.1%), one a delayed bleeding, there were no perforations. <h3>Conclusion</h3> In patients with short Barrett’s segment, non-radical endoscopic Barrett’s resection at the time of scheduled endoscopy follow up allows complete Barrett’s ablation with very low stricture rate. <h3>Disclosure of Interest</h3> None Declared
AB0603 Major Comorbidities of Idiopathic Inflammatory Myositis Affecting Survival and Functional Impairment: A Population-Based Study Using 11 Years of Follow Up from The National Health Insurance in Korea: Table 1.
Authors: J.S. Lee, M.J. Kim, H.Y. Lee, S.Y. Ahn, Y.W. Song, E.B. Lee, E.Y. Lee, Y.J. Lee, E.H. Kang
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with idiopathic inflammatory myositis (IIM) suffer from comorbidities such as interstitial lung disease (ILD), cancer, and infections related to immunosuppressive agents. <h3>Objectives</h3> To evaluate 1) incidence rate ratio (IRRs) of major comorbidities in IIM compared to non-IIM Koreans, and 2) impact of the comorbidities on survival and functional impairment. <h3>Methods</h3> A retrospective cohort study was performed using the 2002–2013 National Health Insurance Service (NHIS) database of weighted probability sampled one million cohort. IIM was identified by at least two visits to the tertiary hospitals under ICD9 code of IIM. Age- and sex-matched twenty subjects per patient, who never had ICD9 code at least for 1 year, were included as the unexposed. The occurrence of ILD, cancer, herpes zoster, and tuberculosis, severely disabled status, and death was captured using ICD9 code, disease-specific medication, and/or government-approved qualification for co-payment reduction on these outcomes. <h3>Results</h3> Ninety-one patients were newly diagnosed as IIM from 2003 to 2013. Most patients (&gt;90%) defined as such were found to have muscle biopsy, electromyogram, or multiple laboratory examinations on muscle enzymes. Their incidence rate of the above outcomes was significantly elevated (Table); IRRs of ILD 31.8 [95% confidence interval: 13.2 – 76.7], cancer 2.36 [1.61–3.48], herpes zoster 1.75 [1.20–2.54], tuberculosis 2.08 [1.15–3.77], severely disabled status 4.79 [2.55–9.01], and mortality 3.47 [1.96–6.12]. Among IIM patients, the presence of ILD or cancer greatly deteriorated survival; mortality IRR of 73.2 [9.58–559.9] in ILD and 63.2 [17.6–226.7] in cancer. The occurrence of zoster and tuberculosis did not influence on the mortality. ILD and cancer also worsened functional impairment of IIM patients; IRR of 12.0 [2.64–54.9] for severely disabled status in ILD and 13.2 [4.19–41.6] in cancer. <h3>Conclusions</h3> This is the first report of the nation-wide population based evaluation of IIM in Korea. The incidence of ILD, cancers, zoster, and tuberculosis was exceptionally higher in IIM than non-IIM. ILD and cancers significantly affected prognosis of IIM. More detailed analysis of comorbidities and their risk factors using the whole national database is underway. <h3>Disclosure of Interest</h3> None declared
The Principal Eosinophil Peroxidase Oxidant, HOSCN, Is a Uniquely Potent Phagocyte Oxidant Inducer of E-Selectin, ICAM-1 and VCAM-1 Expression on Endothelial Cells and Promotes Leukocyte-Endothelial Cell Adhesion. A Potential Mechanism Regulating Leukocyte Trafficking in Eosinophilic Inflammatory States.
Authors: Jianguo Wang, Rong Tang, Yuqing Huo, Arne Slungaard
Journal: Blood (2005)
An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).
Authors: Gloria Mattiuzzi, Amit Lahoti, Abdulla Salahudeen, Farhad Ravandi, Jorge Cortes, Khanh Vu, Hagop Kantarjian
Journal: Blood (2009)
SP0198 A Masterclass on Assessment Questions in Online Courses
Authors: C. Haines
Journal: Annals of the Rheumatic Diseases (2016)

The Educationalist for EULAR, Catherine Haines, will give a brief summary of the crucial importance of assessment in ensuring effective practice for newer entrants to the specialism. The session is suitable for all who are involved in the educational processes in EULAR, including trainees and will focus on: why skilled assessment is important golden rules for skilled assessment quick ways to generate skilled assessment questions <h3>Disclosure of Interest</h3> None declared
Liver Macrophages (Kupffer cells) As Novel Targets of Erythropoietin
Authors: Dafna Gilboa, Yasmin Ohana Haim, Naamit Deshet, Mor Gross, Nathalie Ben-Califa, Max Gassmann, Miriam C. Souroujon, Moshe Mittelman, Drorit Neumann
Journal: Blood (2014)
Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression In Multiple Myeloma Through Modulation Of Wnt/β-Catenin Signaling Pathway
Authors: Yu Zhang, Yong Zhang, Yuji Mishima, Michele Moschetta, Wenjing Zhang, Patricia Maiso, Antonio Sacco, Yosra Aljawai, Ilyas Sahin, Michaela Reagan, Aldo M Roccaro, Irene M. Ghobrial
Journal: Blood (2013)
DELAYED RECOVERY OF ATRIAL REFRACTORINESS AFTER ATRIAL TACHYCARDIA IN THE GOAT
Authors: Cdj Delangen, Rg Tieleman, Hj Vanderwoude, Jg Grandjean, Kj Bel, Mcef Wijffels, Ma Allessie, Hjgm Crijns
Journal: Circulation (1995)
Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group
Authors: Soheil Meshinchi, Todd A. Alonzo, Robert B. Gerbing, Phoenix A. Ho, Alan S. Gamis, Susana C. Raimondi, Betsy A. Hirsch, Todd Cooper, Janet Franklin, Laura Pardo, Michael R. Loken
Journal: Blood (2010)
SAT0618 Efficacy of Two Long-Term Exercise Programs in Patients with Early Rheumatoid Arthritis: Results of 12-Month Randomized Controlled Trial: Table 1
Authors: E. Orlova, D. Karateev, L. Denisov, A. Kochetkov, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> International recommendations and results of randomized controlled trials consider physical exercises, aiming to improve range of motion, aerobic capacity and muscle strength, as an important part of treating rheumatoid arthritis (RA) [1–3]. <h3>Objectives</h3> To compare the efficacy of two 12-month exercise programs in patients with early RA. <h3>Methods</h3> 51 patients with early RA (92,2% females, age of 18 to 53 years, disease duration of 2 to 17 months) were randomized into 3 groups. All patients received methotrexate or leflunomide. At hospital stage 15 patients underwent 10 high-intensity dynamic exercises using gym apparatus Enraf-Nonius with biofeedback for 45–60 min, including aerobic part (En-Cardio) and 18–20 muscle-strengthening exercises (En-Dynamic Track), 18 patients – 10 therapeutic exercises for joints for 45 min under the supervision of a trainer. At outpatient stage the exercises lasted for 12 months 3 times a week. 18 patients received only drug therapy (control). Tender and swollen joint count, pain on 100-mm VAS, erythrocyte sedimentation rate (ESR), DAS28, HAQ, RAPID3, the average powers of knee extension and ankle flexion by EN-TreeM movement analysis were evaluated at baseline and at 12 months. <h3>Results</h3> After 12 months in the both exercise groups there were statistically significant differences from the control group in most parameters (p&lt;0,05), excluding ESR and DAS28 (p&gt;0,05). Efficacy of the gym exercises was higher than the therapeutic exercises by tender joint count, pain on VAS, RAPID3 and extension power of a weaker knee joint (p&lt;0,05). Adherence to the regular therapeutic exercises for 12 months was better (72,2%) then to the gym exercises (53,3%). Predictors of the regular gym exercises were the young age (under 40 years) and the very early stage of RA at the onset of the study. Patients of the both exercise groups, who regularly did exercises during 12 months, had DAS28 low disease activity or remission. <h3>Conclusions</h3> The both long-term exercise programs reduce pain, increase functional status, quality of life and power of motion in early RA patients without negative effect on disease activity. <h3>References</h3> Hurkmans E. et al. Cochrane Database Syst Rev 2009;4:CD006853. De Jong Z. et al. Clin Rheumatol 2009;28(6):663–71. Baillet A. et al. Arthritis Care Res 2010;62:984–92. <h3>Disclosure of Interest</h3> None declared
SP0152 Role of Imaging in The Diagnosis and Treatment of Large Vessel Vasculitis
Authors: T. Bley
Journal: Annals of the Rheumatic Diseases (2016)

Over the past years imaging techniques such as Color-Coded Duplex Sonongraphy (CCDS), Magnetic Resonance Imaging (MRI), Magnetic Resonance Angiography (MRA) and Positron Emission Computed Tomography (PET CT) have greatly improved their diagnostic accuracy for the diagnosis of large vessel vasculitis. This presentation summarises the specific advantages and limitations of CCDS, MRI/MRA and PET CT. CCDS is the diagnostic procedure of first choice in the hands of an experienced observer. CCDS is readily available and may display the so called "halo-sign" of an inflamed vessel wall of the superficial temporal, axillary, carotid, vertebral and subclavian artery. PET CT is thougt to be the most sensitive imaging modality, especially for the assessment of extracranial large artery involvement. PET CT is not as widely available, rather costly and applies radiation. MRI and MRA are noninvasive imaging modalities that display mural inflammatory changes of intracranial, extracranial and large artery involvement. MRI and MRA do not use radiation. In relation to costs and availability MRI and MRA lie somewhere between CCDS and PET CT. Image acquisition in PET CT and MRI/MRA is standardized and largely independent of the operator. Mural inflammatory signs depicted by CCDS, PET CT and MRI/MRA vanish over time under sufficient therapy. However, interpretation of persistant mural changes and imaging of relapsing disease is not yet fully understood. <h3>Disclosure of Interest</h3> T. Bley Grant/research support from: Deutsche Forschungsgemeinschaft, DFG, Consultant for: GSK, MSD, Speakers bureau: Bayer, Bracco, Guerbet, GE, Siemens, HeartFlow
THU0260 IL-25 Axis Is Activated and Associated with An ILC2 and M2 Inflammatory State in Patients with Primary Sjogren's Syndrome
Authors: G. Guggino, F. Ciccia, A. Rizzo, L. Saieva, C. Schinocca, P. Cipriani, R. Giacomelli, R. Alessandro, G. Triolo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Type 2 innate lymphoid cells (ILC2) and M2 polarized macrophages are activated and produce cytokines in response to IL-25/IL-17RB, although the relevance of this axis to immune responses in primary Sjoren9s syndrome (pSS) is unknown. <h3>Objectives</h3> We sought to investigate the role of the IL-25/IL-17RB axis and ILC2 and M2 macrophages in patients with pSS. <h3>Methods</h3> Expression analysis of IL-17B, IL-25, IL-33 and IL-17RB was performed by TaqMan real-time PCR and immunohistochemistry on salivary glands from 50 patients and 20 controls. Analysis of IL-17RB expression and the frequencies of natural type 2 innate lymphoid cells (nILC2), inflammatory ILC2 (iILC2), and M2-polarized macrophages were assessed by means of flow cytometry among salivary gland (SGMC) and peripheral blood (PBMC) mononuclear cells. Clusters of ILC2 cells and M2 macrophages were also studied by immunohistochemistry and confocal microscopy. The role of IL-25 on ILC2 was investigated in <i>ex vivo</i> studies. <h3>Results</h3> IL-25 and IL-17RB, but not IL-25, were significantly over-expressed in the MSG of pSS patients and correlated with the focus score and the degree of lymphoid organization. IL-17RB was mainly expressed by T lymphocytes, ILC2 cells and macrophages. No significant increased expression of IL-33 was observed in pSS. Significant increase in the frequency of iILC2, but not of nILC2, was observed in both PBMC and SGMC. Clusters of ILC2 cells, resembling fat associated lymphoid clusters (FLAC), and M2 polarization were also observed in pSS salivary glands and correlated with the focus score. IL-25 stimulation of isolated SGMC and PBMC resulted in the expansion of iILC2. <h3>Conclusions</h3> These findings suggest that IL-25 may promote, by interacting locally and sistemically with IL-17RB<sup>+</sup> cells, an iILC2 and M2 inflammatory state in pSS. Blockade of the IL-25 axis could be clinically relevant in pSS. <h3>Disclosure of Interest</h3> None declared
Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Clémence Lepelletier, Djaouida Bengoufa, Zeltni Lyes, Adèle de Masson, François Chasset, Marie Jachiet, David Michonneau, Marie Robin, Régis Peffault de Latour, Flore Sicre de Fontbrune, Yacine Tandjaoui-Lambiotte, Armand Bensussan, Michel Rybojad, Abdellatif Tazi, Martine Bagot, Gérard Socié, Anne Bergeron, Jean-David Bouaziz
Journal: JAMA Dermatology (2016)

Chronic graft-vs-host-disease (cGVHD) after allogeneic stem cell transplantation (AHSCT) may resemble autoimmune diseases. Anti-MDA5 (melanoma differentiation-associated gene 5) dermatopulmonary syndrome is a subset of dermatomyositis defined by specific clinical features and detection of anti-MDA5-antibodies in the serum.To characterize the clinical features of patients who underwent AHSCT and screened positively for anti-MDA5 antibodies.For this monocentric retrospective study, we exained 81 patients screened for anti-MDA5 antibodies at a specific dermatological or pulmonary postallograft consultation between January 2014 to September 2015 at a National Reference Center; 2 additional patients not seen at this consultation but having clinical features suggestive of anti-MDA5 syndrome were included. Twenty serum samples from patients after AHSCT without cGVHD were used as controls.Anti-MDA5 antibodies screened using an immunodot assay.Of 83 patients who underwent AHSCT (mean [SD] age, 47 [14] years), 6 patients tested positive for anti-MDA5 antibodies (mean [SD] age, 43 [16] years) including 4 patients with interstitial lung disease and 3 patients with cutaneous clinical features similar to anti-MDA5 skin symptoms encountered in patients who have not undergone AHSCT, namely finger pad inflammation, palmar violaceous papules, and digital ulcerations. Three patients had severe respiratory symptoms resistant to systemic steroids, and 1 patient died of severe interstitial lung disease.The clinical features and long-term prognosis of patients who underwent AHSCT and test positively for anti-MDA5 antibodies should be evaluated in large prospective studies.